MDT-AP-3263
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 9.4
- sex
- M
- new_clusters
- S2
- umap1_2d
- -0.1996102
- umap2_2d
- -9.765090996
- umap1_3d
- -4.177267754
- umap2_3d
- -1.390772533
- umap3_3d
- 6.151116467
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.410
- ANDROGEN_RESPONSE+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- UV_RESPONSE_DN+0.390
- MITOTIC_SPINDLE+0.330
- ANGIOGENESIS+0.320
- PROTEIN_SECRETION+0.320
- TGF_BETA_SIGNALING+0.320
- G2M_CHECKPOINT+0.270
- IL6_JAK_STAT3_SIGNALING+0.260
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.410
- DNA_REPAIR-0.340
- UV_RESPONSE_UP-0.260
- ADIPOGENESIS-0.210
- FATTY_ACID_METABOLISM-0.180
- HEME_METABOLISM-0.140
- P53_PATHWAY-0.110
- MYOGENESIS-0.100
- XENOBIOTIC_METABOLISM-0.090
- PEROXISOME-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A250-01A-31R-A169-07 | — | C | 0.805 |
| 2 | TCGA-A8-A07E-01A-11R-A034-07 | — | A | 0.798 |
| 3 | MDT-AP-3073 | Med | Medulloblastoma | 0.786 |
| 4 | BS_BVSW4GTG | Med | Medulloblastoma | 0.783 |
| 5 | 0801726c-9faf-4905-8cd9-71ad4fc3df25 | — | — | 0.782 |
| 6 | TCGA-HD-7753-01A-11R-2081-07 | — | — | 0.769 |
| 7 | MDT-AP-3075 | Med | Medulloblastoma | 0.757 |
| 8 | TCGA-55-7726-01A-11R-2170-07 | — | cohortSQ1 | 0.755 |
| 9 | MDT-AP-3275 | Med | Medulloblastoma | 0.753 |
| 10 | MDT-AP-3095 | Med | Medulloblastoma | 0.748 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |